GLP-1 weight regain after stopping: what the studies actually say

What did @mattiemaerogers actually say?

Here is the awkward part: the transcript attached to this video is not about GLP-1s at all. It appears to be lyrics or dialogue, not health commentary. So the fact-check is based on the caption, which is the actual health claim being made to 57,000-plus viewers.

The caption argues two things. First, that people who stop GLP-1 medications gain back roughly 5 to 10 pounds. Second, that people who carry good habits forward can maintain their weight after stopping. That second point is the more interesting one, and also the more contested one in the literature.

Does the science back this up?

The 5 to 10 pound figure is significantly too low. The real number is far more alarming, and glossing over it does a disservice to anyone making decisions about long-term use.

The landmark STEP 1 trial extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed participants one year after stopping semaglutide 2.4 mg. Within 68 weeks of discontinuation, participants regained about two-thirds of their prior weight loss. The average loss during treatment was roughly 15 to 17 percent of body weight. Two-thirds of that coming back is not 5 to 10 pounds for most people. For someone who lost 40 pounds, that is closer to 25 to 28 pounds returning. A similar pattern showed up with tirzepatide in the SURMOUNT-4 trial (Aronne et al., 2024, JAMA), where participants who switched from tirzepatide to placebo regained significant weight within the observation period.

The mechanism matters here. GLP-1 receptor agonists work partly by suppressing appetite signals in the brain. When the drug leaves your system, those signals come back. Habits help, but they are competing against neurological appetite drives that the medication was actively suppressing.

What did they get wrong (or right)?

The creator gets partial credit for acknowledging that weight regain happens at all. A lot of GLP-1 content on TikTok pretends the weight loss is permanent by default, which is not what the evidence shows. Naming the phenomenon honestly is a step up from the average influencer take.

But the 5 to 10 pound estimate is misleading in a meaningful way. It implies a modest, manageable rebound. The actual clinical data suggests most people regain a substantial portion of lost weight within one to two years of stopping. Framing the exception, the person with strong habits who maintains well, as the likely outcome without giving the actual average outcome is a classic way misinformation spreads. It is optimistic framing presented as statistical fact.

The claim that maintaining habits will let you "maintain" is also not well supported. Wilding et al. noted that participants in the STEP 1 extension were in a lifestyle intervention program and still regained most of their weight. Habits are not nothing, but they are not a reliable substitute for the pharmacological mechanism the drug was providing.

What should you actually know?

GLP-1 medications are effective while you take them. The evidence on what happens after stopping is consistent and sobering: most weight comes back for most people, even those in structured programs. This does not mean the drugs are not worth taking, but it does mean the conversation about stopping needs to be had with a clinician, not based on a TikTok caption.

If you are considering stopping a GLP-1, the questions worth asking include: what was driving the weight in the first place, what metabolic markers improved during treatment, and what is the realistic maintenance plan given that the appetite suppression will no longer be pharmacologically assisted. There is also emerging research on lower maintenance doses rather than full discontinuation, though that is a clinical conversation, not a self-directed one.

• The STEP 1 extension (Wilding et al., 2022) showed approximately two-thirds of lost weight returning within 68 weeks of stopping semaglutide.
• SURMOUNT-4 (Aronne et al., 2024, JAMA) showed similar regain patterns after tirzepatide discontinuation.
• Lifestyle habits reduce regain somewhat, but do not reliably offset the return of appetite signals that the medication was suppressing.
• Anyone making decisions about stopping a GLP-1 should do so with a licensed prescriber, not a social media caption.